Factors associated with the use of probiotics in patients with inflammatory bowel disease

F1000Research

Volumn 2, Issue , 2013, Pages

  Beales, Ian L P ^a,b   Agathou, Claire Louise ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ALTERNATIVE MEDICINE; ARTICLE; ATTITUDE TO HEALTH; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE DURATION; DRUG USE; EDUCATIONAL STATUS; FEMALE; HEALTH PROMOTION; HUMAN; INFLAMMATORY BOWEL DISEASE; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT PREFERENCE; QUALITY OF LIFE; SEX DIFFERENCE; SHORT INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; STRUCTURED INTERVIEW; STRUCTURED QUESTIONNAIRE; TEACHING HOSPITAL; ULCERATIVE COLITIS; UNITED KINGDOM;

EID: 84914810344     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.2-69.v1     Document Type: Article

References (18)

1. Child M Macfarlane G: The Human Ecosystem. Student BMJ. 2008;16:450-451. 10.1136/sbmj.0812450
2. Leffler DA Lamont JT: Treatment of Clostridium difficile associated disease. Gastroenterology. 2009;136(6):1899-912. 19457418 10.1053/j.gastro.2008.12.070
3. Kim HJ Vazquez Roque MI Camilleri M: A randomized controlled trial of a probiotic combination VSL3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil. 2005;17(5):687-96. 16185307 10.1111/j.1365-2982.2005.00695.x
4. Tung JM Dolovitch LR Lee CH: Prevention of Clostridium difficile diarrhoea infection with Saccharomyces bouladii: a systematic review. Can J Gasttoenterol. 2009;23(12):817-21. 20011734 2805518
5. Summers RW Elliot DE Urban JF Jr: Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology. 2005;128(4):825-32. 15825065 10.1053/j.gastro.2005.01.005
6. Snydman DR: The safety of probiotics. Clin Infect Dis. 2008;46(Suppl 2):S104-11. 18181712 10.1086/523331
7. Targan SR Shannahan F Karp LC: Inflammatory Bowel Disease: From Bench to Bedside. Mechanisms of systemic inflammation associated with intestinal injury. Springer US 2 ndedition,2005;305-335. 10.1007/b136186
8. Gionchetti P Rizzello F Tambasco R: Which therapies are advisable in pouchitis? Inflamm Bowel Dis. 2008;14(Suppl 2):S241-2. 18816748 10.1002/ibd.20709
9. Iweala OI Nagler CR: Immune privilege in the gut: the establishment and maintenance of non-responsiveness to dietary antigens and commensal flora. Immunol Rev. 2006;213(1):82-100. 16972898 10.1111/j.1600-065X.2006.00431.x
10. Koretz RL Rotblatt M: Complementary and alternative medicine in gastroenterology: the good, the bad, and the ugly. Clin Gastroenterol Hepatol. 2004;2(11):957-67. 15551247 10.1016/S1542-3565(04)00461-6
11. Fujita K: Food-drug interactions via human cytochrome P450 3A (CYP3A). Drug Metabol Drug Interact. 2004;20(4):195-217. 15663291 10.1515/DMDI.2004.20.4.195
12. Katan MB: The probiotic yoghurt Activia shortens intestinal transit, but has not been shown to promote defecation. Ned Tijdschr Geneeskd. 2008;152(13):727-30. 18461886
13. Weizman AV Ahn E Thanabalan R: Characteristics of complementary and alternative medicine use and its impact on medication adherence in inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35(3):342-9. 22176478 10.1111/j.1365-2036.2011.04956.x
14. Hilsden RJ Verhoef MJ Best A: Complementary and alternative medicine use by Canadian patients with inflammatory bowel disease: results from a national survey. Am J Gastroenterol. 2003;98(7):1563-8. 12873578 10.1111/j.1572-0241.2003.07519.x
15. Hilsden RJ Meddings JB Verhoef MJ: Complementary and alternative medicine use by patients with inflammatory bowel disease: An internet survey. Can J Gastroenterol. 1999;13(4):327-32. 10360993
16. Joos S Rosemann T Szecsenyi J: Use of complementary and alternative medicine in Germany-a survey of patients with inflammatory bowel disease. BMC Complement Altern Med. 2006;6:19-26. 16716218 10.1186/1472-6882-6-19 1539021
17. Lakatos PL Czegledi Z David G: Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype inpatients with inflammatory bowel disease. J Crohns Colitis. 2010;4(3):283-90. 21122517 10.1016/j.crohns.2009.11.011
18. Jowett SL Seal CJ Barton JR: The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in ulcerative colitis. Am J Gastroenterol. 2001;96(10):2921-8. 11693327 10.1111/j.1572-0241.2001.04682.x